title: Cantharidin treatment for recalcitrant facial flat warts: a preliminary study.
abstract: BACKGROUND
  Topical cantharidin has been reported to be effective and safe in the treatment of cutaneous warts but it has not previously been used for the treatment of facial flat warts.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of topical cantharidin in the treatment of recalcitrant facial flat warts.
  
  
  METHODS
  A total of 15 consecutive patients with recalcitrant facial flat warts were enrolled in this study. Patients having warts near the eye region were excluded from the study. Cantharidin 0.7% solution was applied to treat a maximum of five lesions per session. Repeat therapy was performed at 3-week intervals. Assessment for response and the occurrence of side effects was performed after every session until clinical cure or up to a maximum of 16 weeks.
  
  
  RESULTS
  Of the study population, patients had 8.2 +/- 4.37 lesions before the treatment. The average duration of lesions was 12.6 +/- 6.75 months. All the patients were clinically cured within 16 weeks and the number of required sessions for complete clearance was 2.6 +/- 1.18. Cantharidin therapy was well tolerated, with mild adverse events related to skin.
  
  
  CONCLUSIONS
  Cantharidin is safe and effective when applied to flat warts without occlusion for 4-6 hours every 3 weeks till clear.
authors.affiliation: Department of Dermatology, Ministry of Health Ankara Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey.
authors.forename: Selda Pelinxs
authors.initials: SP
authors.lastname: Kartal Durmazlar
authors.forename: Damla
authors.initials: D
authors.lastname: Atacan
authors.forename: Fatma
authors.initials: F
authors.lastname: Eskioglu
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002193:Cantharidin / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy* / Q000473:pathology; D055815:Young Adult
chemical_list: D002193:Cantharidin